

Special Issue on Hijacking of Endocrine and Metabolic Regulation in Cancer and Diabetes

Call for Papers

Cancer and diabetes are debilitating diseases with the highest impact on health outcomes worldwide. The incidence of these two diseases coexisting is not a chance occurrence. The interaction between diabetes and cancer therapies strongly affects patient treatment outcome. Patients with diabetes have a higher risk of cancer. Commonality in endocrine treatment narrows the gap between the two diseases.

We invite authors to submit original research and review articles that address the interrelationship between cancer and diabetes with a focus on the changing metabolic pathways. We are particularly interested in combined modality treatment for endocrine-resistant disorders. Current concepts in cancer and diabetic treatment using pharmogenetics, stem cells, and viral and nonviral gene therapy animal models and clinical strategies are encouraged. Potential topics include, but are not limited to:

- The link between cancer and diabetes
- Advances in gene therapy for diabetes and/or cancer
- Diabetes and the risk of cancer
- Diabetic treatments and cancer prognosis
- Inflammation, cancer, and diabetes
- The effects of cancer therapies on the diabetic patient
- Combinational therapies to combat endocrine-related disorders: cancer and/or diabetes
- Epidemiological challenges of cancer treatment and diabetic risk
- Inflammatory growth factor signal underlying obesity/diabetes and cancer
- Endocrine resistance and recurrence in cancer: breast, prostate, and ovarian

Before submission authors should carefully read over the journal's Author Guidelines, which are located at <http://www.hindawi.com/journals/bmri/guidelines/>. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/pathology/endo/> according to the following timetable:

Manuscript Due	Friday, 20 June 2014
First Round of Reviews	Friday, 12 September 2014
Publication Date	Friday, 7 November 2014

Lead Guest Editor

Eileen M. McGowan, Translational Cancer Research Group, Medical and Molecular Biosciences, University of Technology, Sydney, NSW 2007, Australia; eileen.McGowan@uts.edu.au

Guest Editors

Ann Simpson, Centre for Health Technologies, University of Technology Sydney, Sydney, NSW 2007, Australia; ann.simpson@uts.edu.au

James McManaman, Division of Basic Reproductive Sciences, Graduate Program in Integrative Physiology, University of Colorado School of Medicine, Denver, CO, USA; jim.mcmanaman@ucdenver.edu

Viroj Boonyaratanakornkit, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, 154 Rama I Road, Wangmai, Pathumwan, Bangkok 10330, Thailand; virojb@me.com

Anandwardhan Hardikar, Sydney Medical School, University of Sydney, NSW 2006 Australia; anand.hardikar@sydney.edu.au